GENITOPE - die Entscheidung naht... - 500 Beiträge pro Seite

[enkelchen]

Genitope ist mit myVax in einer clinical Phase 3 Studie.

Buchwert nach Q2: 2,25$
Kurswert: 3,35$
Aktienanzahl: 42Mio




Settlement
Date Short
Interest Avg Daily
Share Volume Days
to Cover
Sep. 28, 2007 6,624,036 338,471 19.57
Sep. 14, 2007 6,651,542 186,398 35.68
Aug. 15, 2007 7,029,869 161,478 43.53
Jul. 13, 2007 7,401,919 352,750 20.98
Jun. 15, 2007 8,760,358 223,636 39.17
May 15, 2007 7,921,423 437,518 18.11
Apr. 13, 2007 7,318,011 266,187 27.49
Mar. 15, 2007 6,500,063 200,476 32.42
Feb. 15, 2007 5,522,167 217,247 25.42
Jan. 12, 2007 5,061,878 231,826 21.83
Dec. 15, 2006 5,239,016 185,221 28.29
Nov. 15, 2006 5,628,888 188,793 29.82


nun schaue man sich einmal die Optionen Jan08 an.
Fast 16Mio Aktien sind veroptioniert.
Für einen 2,5put (innerer Wert 0)
bekommt man im Moment 1,10$

Verkauft man also heute zu 1,10
und die Aktie fällt zum Verfall unter 2,50
werden die shares zu 2,50 eingebucht.
Abzüglich der Prämie 1,10
hat man die Aktie dann zu 1,40$ erworben.
Das dürfte nach derzeitigem casburn, der dann aktuelle
Buchwert sein.

Bleibt der Kurs über 2,50, streicht man die 110$
Gewinn der Prämie ein.

Meinungen dazu?

Gruss
und

[enkelchen]

Antwort auf Beitrag Nr.: 32.080.481 von enkelchen am 19.10.07 10:56:30

die Leidenszeit der Aktionäre
im Chart ...

[enkelchen]

freefloat ca. 14Mio Aktien

[enkelchen]

Genitope Corporation Initiates Clinical Trial To Evaluate Use Of MyVax Personalized Immunotherapy Following Treatment With Rituximab And Chemotherapy
Main Category: Lymphoma / Leukemia News
Article Date: 22 May 2007 - 0:00 PDT



Genitope Corporation (Nasdaq: GTOP) today announced the initiation of a Phase 2 clinical trial evaluating the use of MyVax(R) personalized immunotherapy following primary treatment with rituximab and chemotherapy (R-Chemo) for follicular non-Hodgkin's lymphoma (fNHL). MyVax(R) personalized immunotherapy is based on the unique genetic makeup of a patient's own tumor and is designed to activate the patient's immune system to fight cancer.

"This is an important trial because it will provide additional information on the optimal timing for use of MyVax(R) personalized immunotherapy following treatment with the current standard of care for patients with fNHL," said Julie Vose, M.D., professor of medicine and chief of the Oncology/Hematology section, University of Nebraska Medical Center. "Initial data have suggested that adding MyVax(R) personalized immunotherapy to the current treatment protocol may extend duration of remission while maintaining a well-tolerated safety profile. We are optimistic this therapy will provide another promising option for the treatment of non-Hodgkin's lymphoma."

Genitope plans to enroll 100 patients in this multi-center, Phase 2, single-arm study at eight leading cancer centers across the United States, including the University of Nebraska Medical Center. The clinical trial is primarily designed to evaluate the efficacy and safety of MyVax(R) personalized immunotherapy following treatment with R-Chemo. Men and women ages 18 years or older who have been diagnosed with previously untreated fNHL, stage III or IV, and who require therapy and are able to receive rituximab and chemotherapy (cyclosphosphamide, vincristine and prednisone either with or without doxorubicin) may be eligible for the study. Eligible patients will receive six to eight cycles of R-Chemo, and after a six-month rest period, will receive a series of 24 immunizations with MyVax(R) personalized immunotherapy over a 92-week period.

"We continue to explore the optimal regimen for MyVax(R) personalized immunotherapy to induce a strong anti-tumor immune response in patients with fNHL," said Mary Ellen Rybak, M.D., vice president of Medical Affairs and chief medical officer at Genitope Corporation. "We hope that data from this Phase 2 trial will provide additional insight on the potential for MyVax(R) personalized immunotherapy to improve survival and alter the natural history of this disease."

MyVax(R) personalized immunotherapy is currently in a pivotal, double-blind, controlled Phase 3 clinical trial to evaluate its safety and efficacy in previously untreated patients with fNHL. In this trial, patients first received chemotherapy to reduce their tumor burden, followed by a 6-month rest period. Patients who maintained at least a partial response through the rest period were then randomized to receive either MyVax(R) personalized immunotherapy or a non-specific immunotherapy, which serves as a control for this trial. Genitope Corporation enrolled 287 patients in this Phase 3 trial. The treatment phase is completed and the protocol-defined follow-up period of the clinical trial is scheduled to conclude at the end of 2007.

NHL is the most common cancer involving B-cells, and is the sixth most common cancer in the United States. There are currently more than 300,000 people in the country living with NHL, with 55,000 new cases diagnosed annually and approximately 32 percent of those diagnoses being new fNHL cases. In addition to clinical trials in fNHL, Genitope Corporation is also exploring the use of MyVax(R) personalized immunotherapy to treat other types of B-cell cancers, including patients with previously untreated chronic lymphocytic leukemia.

About Genitope Corporation

Genitope Corporation (Redwood City, Calif.) is a biotechnology company focused on the research and development of novel immunotherapies for the treatment of cancer. Genitope Corporation's lead product candidate, MyVax(R) personalized immunotherapy, is a patient-specific active immunotherapy based on the unique genetic makeup of a patient's tumor and is designed to activate the patient's immune system to identify and attack cancer cells. For more information on the company, please log on to http://www.genitope.com.

Forward Looking Statements

This news release contains "forward-looking statements." For this purpose, any statements contained in this press release that are not statements of historical fact may be deemed forward-looking statements, including statements regarding the potential of MyVax(R) personalized immunotherapy to extend the duration of remission, improve survival or alter the natural history of follicular non-Hodgkin's lymphoma. Words such as "believes," "anticipates," "plans," "expects," "will," "intends" and similar expressions are intended to identify forward-looking statements. There are a number of important factors that could cause Genitope Corporation's results to differ materially from those indicated by these forward-looking statements, including without limitation, risks related to the progress, timing and results of Genitope Corporation's clinical trials, risks related to competition from other pharmaceutical or biotechnology companies, the risks of growth and dependence on key personnel, risks relating to the manufacturing of MyVax(R) personalized immunotherapy and other risks detailed in Genitope Corporation's filings with the Securities and Exchange Commission, including the Annual Report or Form 10-K for the fiscal year ended December 31, 2006. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Genitope Corporation undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date hereof.

Genitope Corporation
http://www.genitope.com

[zenman]

da isses soweit, oder was ?

The treatment phase is completed and the protocol-defined follow-up period of the clinical trial is scheduled to conclude at the end of 2007.

[enkelchen]

Antwort auf Beitrag Nr.: 32.084.557 von zenman am 19.10.07 15:10:58

soll so sein...

[enkelchen]

Dear Mr. xxx,

Thank you for your inquiry and interest in Genitope
Corporation. An independent Data Safety Monitoring Board
(DSMB) reviewed the second planned interim analysis of
data for efficacy in Genitope’s pivotal Phase 3 clinical
trial for treatment of follicular non-Hodgkin's Lymphoma
(fNHL) and recommended that the trial continue as planned.
The clinical trial will be completed by December 2007.
Any updates regarding Genitope’s studies will be made on
our website (http://www.genitope.com/). Please continue
to check our website for updates.

Best Regards,

Harpreet Nagra

Clinical Research Assistant
Genitope Corporation
Email: [e-mail]
Tollfree Hotline: 1-866-Genitope (1-866-436-4867)
www.genitope.com

[enkelchen]

es rumpelt ein wenig...

[Biotechspezialx]

Antwort auf Beitrag Nr.: 32.834.490 von enkelchen am 21.12.07 08:53:36

Ein wenig ist wohl Untertrieben.......

Nach Börslich 1 $........up

Genitope stock fell 38.9 percent before the announcement to its lowest level since August 2006 before settling at around $1 in extended trade.

[Biotechspezialx]

Antwort auf Beitrag Nr.: 32.836.672 von Biotechspezialx am 21.12.07 12:15:03

GENITOPE CORPORATION
Pre-Market: 1.10 Down 1.49 (-57.53%)

Werden wohl unter 1 $ im laufe des Handels fallen!!!

[enkelchen]

Antwort auf Beitrag Nr.: 32.838.500 von Biotechspezialx am 21.12.07 15:03:49

man sollte einfach nur noch Biotechs shorten...

[Biotechspezialx]

Antwort auf Beitrag Nr.: 32.839.282 von enkelchen am 21.12.07 16:04:19

Ergebnisse sind wohl doch besser!!!!
Die werden gerade wohl zu weit weit nach unten geprügelt!
Achtung die sind sehr zufrieden mit den Ergebnissen. Letzte Meldung hat sich noch nicht rum gesprochen!!!!!!!! Es gibt eine neue Meldung dazu!°

n this pivotal, double-blind, randomized, controlled clinical trial, patients first received chemotherapy to reduce their tumor burden, followed by a 6-month rest period. Patients who maintained at least a partial response through the rest period were then randomized to the MyVax(R) personalized immunotherapy or control arm in a 2:1 ratio. Patients who received MyVax(R) personalized immunotherapy received a patient- and tumor-specific idiotype protein conjugated to a foreign carrier protein called keyhole-limpet hemocyanin (KLH). Patients in the control arm received a non-specific immunotherapy consisting only of KLH. Patients in both arms received granulocyte macrophage-colony stimulating factor (GM-CSF) as an immunologic adjuvant at each immunization.

"We are excited by these results because the data clearly show that MyVax personalized immunotherapy is a safe and active drug for follicular lymphoma patients. Both arms of the trial appear to show activity. Patients who received MyVax personalized immunotherapy and mounted a positive immune response to the tumor-specific target demonstrated superior clinical outcomes compared to patients who did not mount this specific immune response. While we recognize that the regulatory path would be clearer had the trial met its primary endpoint, we are pleased with the outcome of the trial. We are working closely with the FDA to determine the path forward for MyVax personalized immunotherapy," said Dan W. Denney, Jr., Ph.D., chairman and chief executive officer of Genitope Corporation.

............ Das ist eine Intessante wende!!!

[Insider2007]

Was meinen Sie damit?
Was für eine Wende?
Wo sehen Sie den Kurs am Montag?

[Biotechspezialx]

Antwort auf Beitrag Nr.: 32.843.070 von Insider2007 am 21.12.07 19:59:37

Wurde leider erst in einen späteren Meldung Bestätigt – ES sind nicht alle Primär Punkte verfehlt worden! Schlechtes Weihnachtstiming der PR Abteilung der Firma unterschiedliche News zu veröffentlichen!
Aber wenn alle Anleger auf einmal zum Ausgang laufen dann gibt es eh kein halten mehr.

Wenn ich einen Kursverlauf voraus sagen könnte würde ich es mit dem Samstags Lotto mal als Hellseher probieren.
Der Kursverlauf hängt davon ab ob jemand anfängt die Ergebnisse die noch nicht einmal ausgewertet sind richtig zu lesen.
Bei Presseveröffentlichung weiter Daten Pakete wird man wohl noch mehr dazu erfahren!


1..........analysis of a pre-specified endpoint in the MyVax(R) personalized immunotherapy arm showed a highly statistically significant difference in PFS between patients who mounted a positive immune response to the tumor-specific target and those who did not.

2...."We are excited by these results because the data clearly show that MyVax personalized immunotherapy is a safe and active drug for follicular lymphoma patients. Both arms of the trial appear to show activity. Patients who received MyVax personalized immunotherapy and mounted a positive immune response to the tumor-specific target demonstrated superior clinical outcomes compared to patients who did not mount this specific immune response.